Comparing the current results to its competitors, Madrigal Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 126.84 % year on year. The sales growth was above Madrigal Pharmaceuticals Inc 's competitors' average revenue growth of 13.5 %, achieved in the same quarter.
Madrigal Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -36.3 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -36.3 %
Madrigal Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The market for MASH drugs is highly competitive, with Rezdiffra and other product candidates facing competition from pharmaceutical and biotechnology companies globally. Key factors influencing success include efficacy, safety, drug interactions, administration method, pricing, reimbursement, and promotional efforts. Competitors may possess significantly greater financial, technical, research, development, manufacturing, and commercial resources. The company's competitiveness relies on developing differentiated medicines, securing patent protection, obtaining regulatory approvals, successful commercialization, and recruiting qualified personnel. Rezdiffra was the first medication approved by both the FDA and the European Commission for this indication.
Due to outstanding performance in Overall company, revenue grew by 126.84 % Madrigal Pharmaceuticals Inc improved its market share, to approximately 0.25 %.
September 30, 2024
Rezdiffra (resmetirom) Shows Promising Health-Related Quality of Life Improvements in Phase 3 MAESTRO-NASH Trial Madrigal Pharmaceuticals announces the publication of promising health-related quality of life results from the Phase 3 MAESTRO-NASH trial, demonstrating significant improvements in patients with nonalcoholic steatohepatitis. CONSHOHOCKEN, Pa. Sept. 30, 2024 Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a pioneering biopharmaceutical company devoted to developing cutting-edge therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), has recently publicized positive findings from their Phase 3 MAESTRO-NASH clinical trial. The trial evaluates t...
June 6, 2024
Nonalcoholic steatohepatitis (NASH) is an increasingly prevalent liver disease characterized by inflammation and liver cell damage, which can progress to fibrosis, cirrhosis, and ultimately, liver failure. There is a clear unmet need for effective treatment options for NASH patients. In this article, we will examine the latest updates from Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering innovative therapeutics for NASH.Recent Updates from the Phase 3 MAESTRO-NASH Study:Madrigal Pharmaceuticals recently presented exciting results from new analyses of the Phase 3 MAESTRO-NASH trial of Rezdiffra (resmetirom) at the European Association for the Study of the Liver (EASL) Congress...
March 5, 2024
Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis have become significant global health concerns. With limited available treatment options, patients suffering from these conditions face a high risk of developing severe liver-related complications. However, recent advancements in pharmaceutical research have sparked optimism with the validation of Madrigal Pharmaceuticals Marketing Authorization Application (MAA) for resmetirom. This article delves into the potential of resmetirom as a groundbreaking therapeutic approach for NASH/MASH with liver fibrosis.Overview of Resmetirom:Resmetirom, developed by Madrigal Pharmaceuticals, is a novel thera...
February 8, 2024
Madrigal Pharmaceuticals Announces Promising Results for Resmetirom in Phase 3 Trial for NASH TreatmentCONSHOHOCKEN, Pa., Feb. 08, 2024 - Madrigal Pharmaceuticals, a leading clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for nonalcoholic steatohepatitis (NASH), has recently announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of their groundbreaking drug, Resmetirom, in the esteemed New England Journal of Medicine. This publication marks a significant milestone in the journey towards finding an effective treatment for NASH, a chronic and progressive liver disease that affects millions of people worldwide.NASH, also known as fatty liver disease, stems f...
January 4, 2024
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research s at the NASH-TAG Annual ConferenceCONSHOHOCKEN, Pa., Jan. 04, 2024 - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for nonalcoholic steatohepatitis (NASH), has disclosed the presentation of five health economics abstracts at the NASH-TAG Conference. The conference, scheduled from January 4-6, 2024, is being held in Park City, Utah.Madrigal Pharmaceuticals, Inc. is widely recognized for its relentless pursuit of novel therapeutics to combat NASH, a chronic liver disease characterized by fat accumulation in the liver. As a clinical-stag...
Publicly Traded Peers of Madrigal Pharmaceuticals Inc
Syndax Pharmaceuticals Inc Share Performance
-1.29%
Over The Past 5 Days
Syndax Pharmaceuticals Inc
Profile
Syndax Pharmaceuticals Inc has a business model centered around developing innovative cancer treatments. They focus on leveraging their expertise in epigenetics and immuno-oncology to create therapies that target specific cancer types. Syndax collaborates with strategic partners and utilizes clinical trials to bring their treatments to market and improve patient outcomes.
Sellas Life Sciences Group Inc is a biopharmaceutical company that focuses on developing and commercializing immunotherapeutic products for various cancer indications, utilizing innovative technologies. The company aims to meet the need for more effective treatment options by leveraging its expertise in immuno-oncology and precision medicine.
Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company that operates on a business-to-business (B2B) model. They develop and manufacture a wide range of pharmaceutical products and then distribute them to other companies or medical institutions for further distribution or use. Their primary focus is on ensuring the quality and effectiveness of their products while partnering with other entities to ensure their widespread availability in the market.
Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community.
Sources:
Madrigal Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Madrigal Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
